In this issue of the Journal, Antonia and colleagues report the results of the phase 3 PACIFIC study, which evaluated the role of immune checkpoint blockade in locally advanced, unresectable, stage III non–small-cell lung cancer (NSCLC).¹ Eligible patients had disease that had not yet progressed after they had received at least two cycles of platinum-based chemotherapy concurrent with radiotherapy (chemoradiotherapy) at a dose of 54 to 66 Gy. A total of 713 patients were randomly assigned, in a 2:1 ratio, to receive an anti–programmed death ligand 1 (anti–PD-L1) antibody, durvalumab, at a dose of 10 mg per kilogram of body . . .

中文翻译：

---

不可切除的III期非小细胞肺癌的免疫治疗

Antonia及其同事在本期杂志中报告了PACIFIC 3期研究的结果，该研究评估了免疫检查点阻断在局部晚期不可切除的III期非小细胞肺癌（NSCLC）中的作用。¹符合条件的患者在接受了至少两个周期的54到66 Gy放疗的铂类化学疗法与放疗（放化疗）并存后仍未进展。总共以2：1的比例随机分配了713名患者，接受抗编程性死亡配体1（anti-PD-L1）抗体durvalumab，剂量为每公斤身体10 mg。。。